title: A novel chimeric flagellum fused with the multi-epitope vaccine CTB-UE prevents Helicobacter pylori-induced gastric cancer in a BALB/c mouse model.
abstract: Helicobacter pylori (H. pylori) infection causes peptic ulcers, gastric adenocarcinoma, and mucosa-associated lymphoid tissue (MALT) lymphoma. The eradication of H. pylori might be an effective means of preventing gastric cancer. A dual-antigen epitope and dual-adjuvant vaccine called CTB-UE-CF (CCF) was constructed by combining a multi-epitope vaccine CTB-UE with a novel chimeric flagellum (CF) to simultaneously activate Toll-like receptor (TLR) 5-agonist activity and preserve the immunogenicity of H. pylori flagellum FlaA. The evaluation of efficacy to reduce H. pylori colonization was performed using BALB/c mice by oral immunization with a triple dose of this vaccine strain. Two weeks after the last immunization, mice were sacrificed to determine specific antibody levels and proinflammatory cytokine production. To determine the presence of H. pylori, we detected the number of H. pylori by real-time quantitative PCR (qPCR) and measured the urease activity in the gastric tissue. The results showed that the immunogenicity and mucosal immune responses of CCF performed significantly better than those of CTB-UE. This dual-antigen epitope and dual-adjuvant system might greatly contribute to the development of a safe and efficient therapeutic vaccine for humans against H. pylori infection.
authors.affiliation: School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.|Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
authors.forename: Hui
authors.initials: H
authors.lastname: Song
authors.affiliation: School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.|Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
authors.forename: Xiaobo
authors.initials: X
authors.lastname: Lv
authors.affiliation: School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.|Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
authors.forename: Jue
authors.initials: J
authors.lastname: Yang
authors.affiliation: School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.|Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
authors.forename: Wei
authors.initials: W
authors.lastname: Liu
authors.affiliation: School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.|Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
authors.forename: Huan
authors.initials: H
authors.lastname: Yang
authors.affiliation: School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. xitao44@126.com.|Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. xitao44@126.com.
authors.forename: Tao
authors.initials: T
authors.lastname: Xi
authors.affiliation: School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. xitao18@hotmail.com.|Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. xitao18@hotmail.com.
authors.forename: Yingying
authors.initials: Y
authors.lastname: Xing
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D001426:Bacterial Proteins / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology*; D016207:Cytokines / Q000097:blood; D004195:Disease Models, Animal; D000939:Epitopes / Q000276:immunology; D005407:Flagella / Q000235:genetics* / Q000276:immunology; D016481:Helicobacter Infections / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control*; D016480:Helicobacter pylori / Q000235:genetics / Q000254:growth & development / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D006836:Hydro-Lyases / Q000276:immunology; D018928:Immunity, Mucosal; D007114:Immunization; D007115:Immunization Schedule; D008807:Mice, Inbred BALB C; D010088:Oxidoreductases / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000276:immunology; D013274:Stomach Neoplasms / Q000382:microbiology* / Q000517:prevention & control*; D051198:Toll-Like Receptor 5; D014510:Urease / Q000737:chemistry; D014614:Vaccines, Synthetic / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D016207:Cytokines; D000939:Epitopes; C417241:FlaA1 protein, Helicobacter pylori; D011993:Recombinant Fusion Proteins; D051198:Toll-Like Receptor 5; D014614:Vaccines, Synthetic; D010088:Oxidoreductases; D014510:Urease; D006836:Hydro-Lyases
keywords: Adjuvant; Flagellum; Helicobacter pylori; Toll-like receptor 5; Vaccine